Standardimpfung gegen Varizellen

Zusammenfassung

Im Sommer 2004 hat die Ständige Impfkommission (STIKO) am Robert-Koch-Institut eine Empfehlung für die Standardimpfung gegen Varizellen ausgesprochen. Diese Entscheidung hat die Impfdebatte in Deutschland erneut angeheizt, insbesondere aufgrund der nur geringen Bereitschaft der Krankenkassen, die Kosten für die Impfung uneingeschränkt zu übernehmen. Der impfende Kinderarzt steht nun vor dem Problem, den Eltern eine Impfung gegen eine als „harmlos” angesehene Kinderkrankheit nahe zu bringen. Die folgende übersicht soll grundlegende Informationen über das Krankheitsbild und seine Komplikationen sowie über den Impfstoff und seine Anwendung auch in komplexeren Fällen vermitteln.

Summary

The STIKO (german vaccination council) of the Robert Koch institute has recommended a general vaccination programme against varicella by summer 2004. This decision has fueled the debate regarding vaccinations in Germany, especially as health insurance companies have refused to generally reimburse patients for the costs of the vaccination. Pediatricians are now facing the problem of convincing parents of the benefits of a vaccination against a disease generally considered as “harmless”. The following review presents basic information regarding the disease and concomitant complications as well as the vaccine and its usage in complex cases.

Schlüsselwörter

Varizellen - Impfung - STIKO

Keywords

Varicella - vaccination - STIKO

• Literatur

• 1 Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J, Coplan P, Sharrar R, Guess H. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 1999; 18: 1041-6.
• 2 Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpeszoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20: 2500-7.
• 3 Clements DA, Moreira SP, Coplan PM, Bland CL, Walter EB. Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr Infect Dis J 1999; 18: 1047-50.
• 4 Gershon AA. Live-attenuated varicella vaccine. Infect Dis Clin North Am 2001; 15: 65-81 viii.
• 5 Gershon AA. Prevention and treatment of VZV infections in patients with HIV. Herpes 2001; 8: 32-6.
• 6 Ghaffar F, Carrick K, Rogers BB, Margraf LR, Krisher K, Ramilo O. Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency. Pediatr Infect Dis J 2000; 19: 764-6.
• 7 Goldman GS. Incidence of herpes zoster among children and adolescents in a community with moderate varicella vaccination coverage. Vaccine 2003; 21: 4243-9.
• 8 Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 2002; 76: 11447-59.
• 9 Graubner UB, Liese J, Behloradsky BH. Impfungen. Klin Pädiatr 2001; 213: A77-A83.
• 10 Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991; 325: 1545-50.
• 11 Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, Arvin AM. Use of an inactivated varicella vaccine in recipients of hematopoieticcell transplants. N Engl J Med 2002; 347: 26-34.
• 12 Kimmel SR. Vaccine adverse events: separating myth from reality. Am Fam Physician 2002; 66: 2113-20.
• 13 Kramer JM, LaRussa P, Tsai WC, Carney P, Leber SM, Gahagan S, Steinberg S, Blackwood RA. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 2001; 108: E39.
• 14 Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, Provost PJ, Watson BA, Starr SE, Plotkin SA. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991; 9: 643-7.
• 15 Levin MJ, Gershon AA, Weinberg A, Blanchard S, Nowak B, Palumbo P, Chan CY. Immunization of HIV-infected children with varicella vaccine. J Pediatr 2001; 139: 305-10.
• 16 Liese J, Grote V, Fischer R, Belohradsky BH, von Kries R. Varicella – Hospitalisations and Complications in German Children in 2003. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2004
• 17 Ljungman P, Wang FZ, Nilsson C, Solheim V, Linde A. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study. Support Care Cancer 2003; 11: 739-41.
• 18 Nader S, Bergen R, Sharp M, Arvin AM. Age-related differences in cell-mediated immunity to varicella- zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 1995; 171: 13-7.
• 19 Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 2003; 112: e325.
• 20 Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, Arvin AM. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176: 578-85.
• 21 Robert-Koch-Institut. Begründung der STIKO für eine allgemeine Varizellenimpfung. Epidemiol Bull 2004; 49: 421-3.
• 22 Robert-Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert-Koch- Institut/Stand: Juli 2004. Epidemiol Bull 2004; 30: 235-50.
• 23 Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997; 20: 381-3.
• 24 Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K, Li S, Chan I, Heyse J, Waters M, Chan CY, Vessey SJ, Kaplan KM, Kuter BJ. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J 2002; 21: 555-61.
• 25 Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2: 1288-90.
• 26 Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344: 955-60.
• 27 Wagenpfeil S, Neiss A, Banz K, Wutzler P. Empirical data on the varicella situation in Germany for vaccination decisions. Clin Microbiol Infect 2004; 10: 425-30.